203 related articles for article (PubMed ID: 37232394)
1. Advances in minimal residual disease monitoring in multiple myeloma.
Wijnands C; Noori S; Donk NWCJV; VanDuijn MM; Jacobs JFM
Crit Rev Clin Lab Sci; 2023 Nov; 60(7):518-534. PubMed ID: 37232394
[TBL] [Abstract][Full Text] [Related]
2. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
3. Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma.
Oliva S; D'Agostino M; Boccadoro M; Larocca A
Front Oncol; 2020; 10():1. PubMed ID: 32076595
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.
Ferla V; Antonini E; Perini T; Farina F; Masottini S; Malato S; Marktel S; Lupo Stanghellini MT; Tresoldi C; Ciceri F; Marcatti M
Front Oncol; 2022; 12():932852. PubMed ID: 36052251
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
6. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives.
Mina R; Oliva S; Boccadoro M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32645952
[TBL] [Abstract][Full Text] [Related]
7. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
8. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
9. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
10. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
11. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
Kothari S; Hillengass J; McCarthy PL; Holstein SA
Curr Hematol Malig Rep; 2019 Feb; 14(1):39-46. PubMed ID: 30671912
[TBL] [Abstract][Full Text] [Related]
12. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
[TBL] [Abstract][Full Text] [Related]
13. Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma.
Foureau DM; Paul BA; Guo F; Lipford EH; Fesenkova K; Tjaden E; Drummond K; Bhutani M; Atrash S; Ndiaye A; Varga C; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e41-e50. PubMed ID: 36443182
[TBL] [Abstract][Full Text] [Related]
14. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Anderson KC; Auclair D; Adam SJ; Agarwal A; Anderson M; Avet-Loiseau H; Bustoros M; Chapman J; Connors DE; Dash A; Di Bacco A; Du L; Facon T; Flores-Montero J; Gay F; Ghobrial IM; Gormley NJ; Gupta I; Higley H; Hillengass J; Kanapuru B; Kazandjian D; Kelloff GJ; Kirsch IR; Kremer B; Landgren O; Lightbody E; Lomas OC; Lonial S; Mateos MV; Montes de Oca R; Mukundan L; Munshi NC; O'Donnell EK; Orfao A; Paiva B; Patel R; Pugh TJ; Ramasamy K; Ray J; Roshal M; Ross JA; Sigman CC; Thoren KL; Trudel S; Ulaner G; Valente N; Weiss BM; Zamagni E; Kumar SK
Clin Cancer Res; 2021 Oct; 27(19):5195-5212. PubMed ID: 34321279
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Perrot A; Lauwers-Cances V; Corre J; Robillard N; Hulin C; Chretien ML; Dejoie T; Maheo S; Stoppa AM; Pegourie B; Karlin L; Garderet L; Arnulf B; Doyen C; Meuleman N; Royer B; Eveillard JR; Benboubker L; Dib M; Decaux O; Jaccard A; Belhadj K; Brechignac S; Kolb B; Fohrer C; Mohty M; Macro M; Richardson PG; Carlton V; Moorhead M; Willis T; Faham M; Anderson KC; Harousseau JL; Leleu X; Facon T; Moreau P; Attal M; Avet-Loiseau H; Munshi N
Blood; 2018 Dec; 132(23):2456-2464. PubMed ID: 30249784
[TBL] [Abstract][Full Text] [Related]
16. New criteria for response assessment: role of minimal residual disease in multiple myeloma.
Paiva B; van Dongen JJ; Orfao A
Blood; 2015 May; 125(20):3059-68. PubMed ID: 25838346
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
18. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
Front Oncol; 2019; 9():689. PubMed ID: 31555576
[TBL] [Abstract][Full Text] [Related]
19. Role of minimal residual disease assessment in multiple myeloma.
Szalat R; Anderson K; Munshi N
Haematologica; 2024 Feb; ():. PubMed ID: 38328864
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Diamond B; Korde N; Lesokhin AM; Smith EL; Shah U; Mailankody S; Hultcrantz M; Hassoun H; Lu SX; Tan C; Rustad EH; Maura F; Maclachlan K; Peterson T; Derkach A; Devlin S; Landau HJ; Scordo M; Chung DJ; Shah GL; Lahoud O; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Giralt SA; Landgren O
Lancet Haematol; 2021 Jun; 8(6):e422-e432. PubMed ID: 34048681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
